The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

GSK plc has entered into agreements with China-based biotechnology company Hengrui Pharma to develop up to 12 innovative ...

GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious diseases, including HIV, but the ABL deal and others signed in recent ...

GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

Also on Trump’s mind is the Federal Reserve. Its chair Jay Powell will on Wednesday unveil the US central bank’s decision on interest rates. The uncomfortable relationship between the president and ...